| Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage … ND James, MR Sydes, NW Clarke, MD Mason, DP Dearnaley, MR Spears, ... The Lancet 387 (10024), 1163-1177, 2016 | 2136 | 2016 |
| Abiraterone for prostate cancer not previously treated with hormone therapy ND James, JS de Bono, MR Spears, NW Clarke, MD Mason, ... New England Journal of Medicine 377 (4), 338-351, 2017 | 1813 | 2017 |
| Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial CC Parker, ND James, CD Brawley, NW Clarke, AP Hoyle, A Ali, ... The Lancet 392 (10162), 2353-2366, 2018 | 1121 | 2018 |
| Addition of docetaxel to hormonal therapy in low-and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial NW Clarke, A Ali, FC Ingleby, A Hoyle, CL Amos, G Attard, CD Brawley, ... Annals of Oncology 30 (12), 1992-2003, 2019 | 386 | 2019 |
| Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol MR Sydes, MR Spears, MD Mason, NW Clarke, DP Dearnaley, ... Annals of Oncology 29 (5), 1235-1248, 2018 | 278 | 2018 |
| Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised … G Attard, L Murphy, NW Clarke, W Cross, RJ Jones, CC Parker, ... The lancet 399 (10323), 447-460, 2022 | 255 | 2022 |
| STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive … ND James, MR Sydes, NW Clarke, MD Mason, DP Dearnaley, MR Spears, ... Lancet 387 (10024), 1163-1177, 2016 | 219 | 2016 |
| Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial ND James, MR Spears, NW Clarke, DP Dearnaley, MD Mason, CC Parker, ... JAMA oncology 2 (3), 348-357, 2016 | 215 | 2016 |
| Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial ND James, MR Sydes, MD Mason, NW Clarke, J Anderson, DP Dearnaley, ... The lancet oncology 13 (5), 549-558, 2012 | 130 | 2012 |
| Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. Radiotherapy to the primary tumour for newly diagnosed … CC Parker, ND James, CD Brawley, NW Clarke, AP Hoyle, A Ali, ... Lancet 392 (10162), 2353-2366, 2018 | 126 | 2018 |
| Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab S Lin, NA Kennedy, A Saifuddin, DM Sandoval, CJ Reynolds, RC Seoane, ... Nature communications 13 (1), 1379, 2022 | 81 | 2022 |
| Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial CC Parker, ND James, CD Brawley, NW Clarke, A Ali, CL Amos, G Attard, ... PLoS medicine 19 (6), e1003998, 2022 | 62 | 2022 |
| Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476) ND James, NW Clarke, A Cook, A Ali, AP Hoyle, G Attard, CD Brawley, ... International Journal of Cancer 151 (3), 422-434, 2022 | 48 | 2022 |
| Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): An open-label, non … JE Brown, KL Royle, W Gregory, C Ralph, A Maraveyas, O Din, T Eisen, ... The Lancet Oncology 24 (3), 213-227, 2023 | 36 | 2023 |
| Prospective observational study of pazopanib in patients with advanced renal cell carcinoma (PRINCIPAL study) M Schmidinger, A Bamias, G Procopio, R Hawkins, AR Sanchez, ... The Oncologist 24 (4), 491-497, 2019 | 35 | 2019 |
| Addition of docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): modelling to estimate long-term survival, quality-adjusted survival, and cost … BS Woods, E Sideris, MR Sydes, MR Gannon, MKB Parmar, M Alzouebi, ... European urology oncology 1 (6), 449-458, 2018 | 29 | 2018 |
| Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two … G Attard, L Murphy, NW Clarke, A Sachdeva, C Jones, A Hoyle, W Cross, ... The Lancet Oncology 24 (5), 443-456, 2023 | 28 | 2023 |
| Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer … CM Nutting, JP Morden, M Beasley, S Bhide, A Cook, E De Winton, ... European Journal of Cancer 103, 249-258, 2018 | 28 | 2018 |
| Impaired postoperative neutrophil leucocytosis and acute complications following short course preoperative radiotherapy for operable rectal cancer A Hartley, S Giridharan, N Srihari, C McConkey, JI Geh European Journal of Surgical Oncology (EJSO) 29 (2), 155-157, 2003 | 27 | 2003 |
| Observation versus screening spinal MRI and pre-emptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases in the … D Dearnaley, V Hinder, A Hijab, G Horan, N Srihari, P Rich, JG Houston, ... The Lancet Oncology 23 (4), 501-513, 2022 | 19 | 2022 |
Matthew R SydesMRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University CollegeVerified email at ucl.ac.uk
